The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO

Haemophilia. 2016 Jul;22(4):487-98. doi: 10.1111/hae.13013. Epub 2016 Jun 16.

Abstract

Enhanced half-life factor VIII and IX products are being introduced into routine clinical practice. Published data report on clinical trials and there are limited data available on how to use these products in routine clinical practice. Many patients, for example, those with a past history of an inhibitor, have been excluded from clinical trials and there are limited data published on children. This guidance document is a consensus statement from the UK Haemophilia Centres Doctors' Organisation and aims to give pragmatic advice on the use of these products in routine practice.

Keywords: coagulation factor concentrates; enhanced half-life; pharmacokinetics; prophylaxis.

Publication types

  • Practice Guideline
  • Review

MeSH terms

  • Antibodies, Neutralizing / blood
  • Coagulants / chemistry
  • Coagulants / pharmacokinetics
  • Coagulants / therapeutic use*
  • Factor IX / chemistry
  • Factor IX / pharmacokinetics
  • Factor IX / therapeutic use*
  • Factor VIII / chemistry
  • Factor VIII / pharmacokinetics
  • Factor VIII / therapeutic use*
  • Half-Life
  • Hemophilia A / drug therapy*
  • Hemophilia B / drug therapy*
  • Hemorrhage / prevention & control
  • Humans
  • Polyethylene Glycols / chemistry
  • Recombinant Fusion Proteins / biosynthesis
  • Recombinant Fusion Proteins / pharmacokinetics
  • Recombinant Fusion Proteins / therapeutic use

Substances

  • Antibodies, Neutralizing
  • Coagulants
  • Recombinant Fusion Proteins
  • Polyethylene Glycols
  • Factor VIII
  • Factor IX